Back to Search
Start Over
Elevated Stratifin promotes cisplatin-based chemotherapy failure and poor prognosis in non-small cell lung cancer.
- Source :
-
Molecular therapy oncolytics [Mol Ther Oncolytics] 2021 Jul 21; Vol. 22, pp. 326-335. Date of Electronic Publication: 2021 Jul 21 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Drug resistance is a key factor in the treatment failure of clinical non-small cell lung cancer (NSCLC) patients after adjuvant chemotherapy. Here, our results provide the first evidence that eukaryotic translation initiation factor 2b subunit delta (EIF2B4)-Stratifin (SFN) fusion and increased SFN expression are associated with chemotherapy tolerance and activation of the phosphatidylinositol 3 kinase/v-akt murine thymoma viral oncogene (PI3K/Akt) signaling pathway in NSCLC patients, suggesting that SFN might have potential prognostic value as a tumor biomarker for the prognosis of patients with NSCLC.<br />Competing Interests: The authors declare no competing interests.<br /> (© 2021 The Author(s).)
Details
- Language :
- English
- ISSN :
- 2372-7705
- Volume :
- 22
- Database :
- MEDLINE
- Journal :
- Molecular therapy oncolytics
- Publication Type :
- Academic Journal
- Accession number :
- 34553022
- Full Text :
- https://doi.org/10.1016/j.omto.2021.07.005